Evidence map›Paper›PMID 41674229›Full record

ArticleDiabetes, obesity & metabolism2026

Real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi-site retrospective study.

Yusuke Minakata, Masaki Miura, Nobuhiro Nakatake, Masahiro Masuzawa

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yusuke MinakataDiabetes and Endocrinology, Kameda Medical Center, Kamogawa, Japan.ORCID 0009-0000-8062-1365
Masaki MiuraDiabetes and Endocrinology, Kameda Medical Center, Kamogawa, Japan.
Nobuhiro NakatakeDiabetes and Endocrinology, Kameda Medical Center, Kamogawa, Japan.
Masahiro MasuzawaDiabetes and Endocrinology, Kameda Medical Center, Kamogawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDespite the established efficacy of tirzepatide in randomised controlled trials, real-world effectiveness data in Japanese patients remain limited. This study evaluated the real-world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes over 52 weeks. MATERIALS AND

methodsThis multi-site retrospective cohort study analysed 203 Japanese patients with type 2 diabetes who initiated tirzepatide at three outpatient clinics between July 2023 and August 2024. The primary endpoint was HbA1c change at 52 weeks. Subgroup analyses were performed on 22 predefined patient characteristics.

resultsThe mean baseline HbA1c was 7.7%, and the mean body mass index was 29.1 kg/m

conclusionsTirzepatide demonstrated clinically meaningful HbA1c reductions with favourable safety profiles in Japanese patients. The effectiveness was consistent across diverse subgroups, supporting its integration into diabetes management in Japan.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsTirzepatideAgedBlood GlucoseEast Asian PeopleFemaleGlycated HemoglobinHumansIncretinsJapanMaleMiddle AgedRetrospective StudiesTreatment OutcomeBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsIncretinsTirzepatideGIPGLP‐1incretin therapyreal‐world evidencetype 2 diabetes

Identifiers

PMID41674229
PMCPMC13071243

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.